Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. The business had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. On average, analysts expect Y-mAbs Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Stock Down 0.6 %

Y-mAbs Therapeutics stock opened at $17.15 on Friday. Y-mAbs Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $20.90. The company has a 50 day moving average price of $15.71 and a 200-day moving average price of $10.92.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of Y-mAbs Therapeutics stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the transaction, the senior vice president now directly owns 33,889 shares of the company’s stock, valued at $560,185.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 21.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on YMAB. Canaccord Genuity Group upped their target price on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. HC Wainwright boosted their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Wedbush reiterated an “outperform” rating and set a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Finally, BMO Capital Markets boosted their price objective on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $16.57.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.